Archive for the News Category

Ceapro Inc. Reports 2018 First Quarter Results

EDMONTON, ALBERTA – May 17, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the quarter ended March 31, 2018.

Read more

Ceapro Inc. Presents PGX Enabling Technology Case Study at the 12th International Symposium on Supercritical Fluids – Ceapro receives issued European Patent for PGX Technology – Poster presentation on a new PGX-dried chemical complex gum Arabic/CoQ10

EDMONTON, ALBERTA – April 25, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Bernhard Seifried, Ph.D., Ceapro’s Director of Engineering Research and Technology, and

Read more

Ceapro Inc. Provides Corporate Update – Company well poised to transition to its next phase of growth for expansion into the profitable nutraceutical sector over the next 12 months – Data expected from the bioavailability study of CoQ10-beta glucan and results of the avenanthramides in exercise-induced inflammation in Q2 2018

EDMONTON, ALBERTA – April 23, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a summary of 2017 key accomplishments and recent highlights. “We have made

Read more

Ceapro Inc. Reports 2017 Financial Results – Year marked by increased investments in product pipeline and enabling technologies

EDMONTON, ALBERTA – April 20, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve months ended December 31, 2017. Ceapro

Read more

Ceapro Inc. Announces Important Collaboration with Prestigious Montreal Heart Institute – Beta-glucan project expected to be Ceapro’s first clinical project led by MHI’s Montreal Health Innovations Coordinating Center (MHICC)

EDMONTON, ALBERTA – April 18, 2018 – Ceapro Inc. (TSX-V: CZO), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has established a long-term formal collaboration with the prestigious Montreal Heart Institute (MHI). While

Read more

Ceapro Inc. to Present at the 12th International Symposium on Supercritical Fluids

EDMONTON, ALBERTA – April 13, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the 12th International Symposium on Supercritical Fluids

Read more

Ceapro Announces Acceptance of Abstract for Presentation at the Nutrition 2018 Meeting

EDMONTON, ALBERTA – April 3, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the American Society for Nutrition’s inaugural flagship

Read more

Ceapro to Present at the Wall Street Investor Forum – Presentation with live webcast on Thursday, March 22nd at 10:20 a.m. ET

EDMONTON, ALBERTA – March 15, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon M.Sc., MBA, Ceapro’s President and Chief Executive Officer, will

Read more

Ceapro Inc. to Consider Judgements in AVAC Ltd. Actions

EDMONTON, ALBERTA – January 29, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Mr. Justice C.M. Jones issued his written decision with respect to

Read more

Ceapro to Present at Noble Capital Markets’ 14th Annual Investor Conference – Presentation with live video webcast on Tuesday, January 30th at 2:00 p.m. EST

EDMONTON, ALBERTA – January 17, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon M.Sc., MBA, Ceapro’s President and Chief Executive Officer, will

Read more
Page 1 of 1212345...10...Last »